--- title: "Weekly Recap | Phillip Morris -1.13%, FDA nod for 11 new nicotine pouches" type: "News" locale: "en" url: "https://longbridge.com/en/news/296670000.md" description: "Phillip Morris (PM) slipped 1.13% this week to close at $188.23, yet still outperformed the S&P 500 by roughly 0.3 percentage points, as the benchmark fell 1.43%. The stock swung through a 5.29% range in a choppy five-day stretch. Monday (17 Aug) saw a sharp sell-off to a weekly low of $184.52. A three-day recovery followed, pushing the stock to a weekly high of $194.26 on Thursday (20 Aug). Friday (21 Aug) gave back the gains, with the stock settling at $188." datetime: "2026-08-22T05:31:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296670000.md) - [en](https://longbridge.com/en/news/296670000.md) - [zh-HK](https://longbridge.com/zh-HK/news/296670000.md) generator: "portal-rs" --- # Weekly Recap | Phillip Morris -1.13%, FDA nod for 11 new nicotine pouches ## The Week Phillip Morris (PM) slipped 1.13% this week to close at $188.23, yet still outperformed the S&P 500 by roughly 0.3 percentage points, as the benchmark fell 1.43%. The stock swung through a 5.29% range in a choppy five-day stretch. Monday (17 Aug) saw a sharp sell-off to a weekly low of $184.52. A three-day recovery followed, pushing the stock to a weekly high of $194.26 on Thursday (20 Aug). Friday (21 Aug) gave back the gains, with the stock settling at $188.23, just below the week’s open. Average daily volume of about 5.4m shares ran 16% above the 60-day median, pointing to a pickup in turnover. ## Key Events The standout development came late in the week: the FDA authorised 11 new nicotine pouches, strengthening PM’s reduced-risk product portfolio. This was the most consequential fundamental signal of the week. Earlier, the news flow was dominated by institutional positioning. Bronte Capital disclosed on 17 Aug that PM was its seventh-largest holding, and later in the week, Csenge Advisory Group and Main Street Financial Solutions disclosed new or increased stakes. A Wall Street strategist roundup also highlighted PM as a high-dividend defensive play. Meanwhile, daily market-wire reports noted that the stock underperformed its tobacco peers on most sessions, even on days when it posted gains. ## Analyst Ratings A total of 17 analysts cover Phillip Morris, placing it first among 10 names in the tobacco industry. The breakdown: 8 rate it buy, 4 rate it overweight, 4 rate it hold, and 1 has no opinion; no analyst rates it underweight or sell. The consensus recommendation stands at ‘buy’, with a consensus target of $203.80, implying roughly 8.3% upside from the current price. The target range is wide — from $175.00 to $225.00 — but even the low end sits near the current level, suggesting most analysts see limited downside risk. ## The Week Ahead Macro data takes centre stage on Tuesday, 25 Aug, with a cluster of US housing indicators — the FHFA Home Price Index, Case-Shiller 20-City Index, and new home sales — alongside the Conference Board’s consumer confidence reading. These prints will offer fresh clues on the health of the US consumer. For PM, the next firm catalyst is the Q3 FY2026 earnings release on 21 October, with the Street looking for earnings of about $2.10 per share and revenue near $11.2bn. That report will be the next real test of the reduced-risk narrative. ## In Short PM drifted lower this week but held up better than the broader market, keeping its defensive character intact. The analyst consensus is supportive, with a buy rating and a target above spot, and institutional buying through the week adds a layer of professional conviction. The FDA nod for new pouches is a forward-looking positive, but the payoff is still some way off. The tension now is between a favourable rating backdrop and the wait for hard numbers — the next quarterly report is the key checkpoint for whether the reduced-risk story can lift the stock beyond its current range. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [PM.US](https://longbridge.com/en/quote/PM.US.md) ## Related News & Research - [Callan Family Office LLC Buys New Shares in Philip Morris International Inc. $PM](https://longbridge.com/en/news/296676971.md) - [Philip Morris gets FDA nod for 11 new nicotine pouches](https://longbridge.com/en/news/296645610.md) - [43,892 Shares in Philip Morris International Inc. $PM Acquired by Csenge Advisory Group](https://longbridge.com/en/news/296457106.md) - [Main Street Financial Solutions LLC Acquires Shares of 8,058 Philip Morris International Inc. $PM](https://longbridge.com/en/news/296468700.md) - [Philip Morris International Inc. $PM is Bronte Capital Management Pty Ltd.'s 7th Largest Position](https://longbridge.com/en/news/296072310.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**